FN2 Earnings Intelligence
Charles River Laboratories International, Inc. financials
Charles River Laboratories International, Inc. (CRL) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 | 12/27/2026 est. | 12/27/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $241.2 | $233.9 | $276.8 | $194.6 | $213.8 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,540.2 | $3,976.1 | $4,129.4 | $4,050 | $4,015.4 | $3,849.8 | $3,918.2 |
| % Growth | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% | -4.1% | 1.8% |
| Gross Profit | $1,702.7 | $1,832.7 | $1,833.4 | $1,704.2 | $1,700.6 | - | - |
| % Margin | 48.1% | 46.1% | 44.4% | 42.1% | 42.4% | - | - |
| EBITDA | $855.4 | $954.8 | $931.4 | $589.1 | $428.5 | - | - |
| % Margin | 24.2% | 24.0% | 22.6% | 14.5% | 10.7% | - | - |
| Net Income | $391 | $486.2 | $474.6 | $22.2 | -$144.3 | - | - |
| % Margin | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% | - | - |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 | $11.11 | $12.35 |
| % Growth | 5.6% | 24.7% | -2.7% | -97.8% | -1,555.0% | 481.6% | 11.2% |
| Operating Cash Flow | $760.8 | $619.6 | $683.9 | $734.6 | $737.6 | - | - |
| CapEx | $228.8 | $324.7 | $318.5 | $233 | $219.2 | - | - |
| Free Cash Flow | $532 | $294.9 | $365.4 | $501.6 | $518.5 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 | 12/27/2026 est. | 12/27/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,540.2 | $3,976.1 | $4,129.4 | $4,050 | $4,015.4 | $3,849.8 | $3,918.2 |
| Gross Profit | $1,702.7 | $1,832.7 | $1,833.4 | $1,704.2 | $1,700.6 | - | - |
| EBITDA | $855.4 | $954.8 | $931.4 | $589.1 | $428.5 | - | - |
| Net Income | $391 | $486.2 | $474.6 | $22.2 | -$144.3 | - | - |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 | $11.11 | $12.35 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $241.2 | $233.9 | $276.8 | $194.6 | $213.8 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $760.8 | $619.6 | $683.9 | $734.6 | $737.6 |
| Capital Expenditure | $228.8 | $324.7 | $318.5 | $233 | $219.2 |
| Free Cash Flow | $532 | $294.9 | $365.4 | $501.6 | $518.5 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/28/2024 | 12/27/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% |
| Gross Margin | 48.1% | 46.1% | 44.4% | 42.1% | 42.4% |
| EBITDA Margin | 24.2% | 24.0% | 22.6% | 14.5% | 10.7% |
| Net Margin | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
| FCF Margin | 15.0% | 7.4% | 8.8% | 12.4% | 12.9% |
| Diluted EPS Growth | 5.6% | 24.7% | -2.7% | -97.8% | -1,555.0% |